Was the Chemours (CC) share grant to George R. Brokaw an open-market purchase?

No, the 7,182-share transaction for George R. Brokaw is coded as a grant or award. The reported price is $0.00 per share, indicating compensation-related stock rather than an open-market purchase, which would normally show a positive purchase price per share.

Chemours (NYSE: CC) director granted 7,182 shares in equity award

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Brokaw George R reported acquisition or exercise transactions in this Form 4 filing.

Director George R. Brokaw of Chemours Co received an award of 7,182 shares of Common Stock on May 6, 2026. The shares were granted at $0.00 per share as compensation rather than a market purchase. Following this grant, his direct holdings, including deferred stock units and dividend equivalent units, total 21,642.7173 shares of Chemours common stock.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Brokaw George R

Role null

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	7,182	$0.00	--

Holdings After Transaction: Common Stock — 21,642.717 shares (Direct, null)

Footnotes (1)

[object Object]

Key Figures

Stock award: 7,182 shares Award price: $0.00 per share Total holdings after grant: 21,642.7173 shares

3 metrics

Stock award 7,182 shares Common Stock grant on May 6, 2026

Award price $0.00 per share Grant/award acquisition, non-market transaction

Total holdings after grant 21,642.7173 shares Direct holdings including deferred and dividend equivalent units

Key Terms

deferred stock units, dividend equivalent units, Grant, award, or other acquisition, Common Stock

4 terms

deferred stock units financial

"Includes deferred stock units and dividend equivalent units."

Deferred stock units are promises from a company to give an employee shares of stock at a future date, often after certain conditions are met or after leaving the company. They function like a form of delayed compensation, allowing employees to earn shares over time. For investors, they represent potential future ownership in the company, but do not provide immediate voting rights or dividends until the shares are actually received.

dividend equivalent units financial

"Includes deferred stock units and dividend equivalent units."

Dividend equivalent units are bookkeeping credits that mirror cash dividends paid on actual shares, granted to holders of stock-based awards such as restricted stock units or deferred compensation. They matter to investors because they increase a company’s reported employee compensation cost and can lead to issuance of more shares or cash payouts over time, similar to extra pay linked to ownership that affects shareholder dilution and corporate cash flow.

Grant, award, or other acquisition financial

"transaction_code_description": "Grant, award, or other acquisition""

Common Stock financial

"security_title": "Common Stock""

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

Form 4 Insider Transactions: What Each Field Means →

05/08/2026 - 04:15 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Brokaw George R

(Last)

(First)

(Middle)

C/O THE CHEMOURS COMPANY

1007 MARKET STREET

(Street)

WILMINGTON

DELAWARE

19801

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Chemours Co [ CC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/06/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	05/06/2026		A		7,182	A	$0	21,642.7173⁽¹⁾	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. Includes deferred stock units and dividend equivalent units.

	/s/ Eric Stein, Attorney-in-Fact	05/08/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Chemours (CC) director George R. Brokaw report?

George R. Brokaw reported receiving an award of 7,182 shares of Chemours Common Stock. The Form 4 shows this as a grant or other acquisition, not an open-market trade, reflecting equity-based compensation rather than a typical buy or sell transaction.

How many Chemours (CC) shares does George R. Brokaw hold after this Form 4 transaction?

After the reported grant, George R. Brokaw holds a total of 21,642.7173 Chemours Common Stock units directly. This figure includes deferred stock units and dividend equivalent units, as noted in the filing footnote attached to his reported holdings.

What does the transaction code "A" mean in the Chemours (CC) Form 4 for George R. Brokaw?

The transaction code “A” on George R. Brokaw’s Form 4 indicates a grant, award, or other acquisition. In this case, it represents 7,182 shares of Chemours Common Stock received as an equity award rather than a traditional market buy or sell.

Are derivative securities involved in George R. Brokaw’s Chemours (CC) Form 4 filing?

No derivative transactions are shown in this Form 4. The filing lists only a non-derivative Common Stock award, and the derivative summary section is empty, indicating no option exercises, warrant conversions, or other derivative activity reported in this transaction.

What does the footnote about deferred stock units mean in the Chemours (CC) Form 4?

The footnote explains that Brokaw’s reported total of 21,642.7173 Chemours units includes deferred stock units and dividend equivalent units. These represent share-based credits that track the value of the stock, usually as part of director compensation programs.